In contrast, patients with increased expression of other four HSPs (poor prognosis) had higher clinical stage (HSP90AA1 p < 0,0001; CCT1 p = 0,0277; CCT2 p = 0,0005; CCT6A p = 0,0185), larger tumors (HSP90AA1 p < 0,0001; CCT1 p < 0,0001; CCT2 p = 0,0003; CCT6A p < 0,0001), more lymph nodes involved (HSP90AA1 p = 0,0139; CCT2 p = 0,003), ER-negative cancers (HSP90AA1 p = 0,0015; CCT1 p < 0,0001; CCT6A p < 0,0001), PR-negative cancers (HSP90AA1 p < 0,0001; CCT1 p < 0,0001; CCT6A p < 0,0001) and HER2-positive cancers (HSP90AA1 p < 0,0001; CCT1 p < 0,0001; CCT2 p = 0,0002; CCT6A p = 0,0075). This evidence concerns the gene ESR1 and cancer.